by
Barbara Kram, Editor | February 03, 2009
"Since we received approval of SNM's centralized IND, several pharmaceutical developers have expressed interest in using FLT in near-term clinical trial multi-center work," said Atcher. "That's the real validation that this effort was worthwhile."
Active clinical trials utilizing FLT are expected to begin in 2009. For more information about the SNM Clinical Trials Network, please visit www.snm.org/ClinicalTrials.
Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Members of the press should contact Amy Shaw, (703) 652-6773 or ashaw@snm.org, or Kathryn Wiley, (703) 326-1184 or kwiley@snm.org, for more information or to schedule interviews with SNM Clinical Trials Network leadership.
About SNM
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org.
Back to HCB News
